<SEC-DOCUMENT>0001171843-20-001901.txt : 20200323
<SEC-HEADER>0001171843-20-001901.hdr.sgml : 20200323
<ACCEPTANCE-DATETIME>20200323080019
ACCESSION NUMBER:		0001171843-20-001901
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200323
FILED AS OF DATE:		20200323
DATE AS OF CHANGE:		20200323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		20733619

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_032320.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;UNITED STATES&nbsp;</B>&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C.&nbsp;20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>FORM 6-K</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>of&nbsp;the Securities Exchange Act of 1934</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">For the month of March 2020<BR>
Commission File No.:001-35773</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>REDHILL BIOPHARMA LTD.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>21 Ha'arba'a Street, Tel Aviv, 6473921, Israel</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Address of principal executive offices)</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 28.35pt; margin: 0pt 0">Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 14.2pt; margin: 0pt 0">Form 20-F&nbsp;&#9746;&nbsp;Form 40-F&nbsp;&#9744;</P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 14.2pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 28.35pt; margin: 0pt 0">Indicate by check mark if the Registrant is&nbsp;submitting&nbsp;the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 28.35pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 28.35pt; margin: 0pt 0">Indicate by check mark if the Registrant is&nbsp;submitting&nbsp;the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Attached hereto and incorporated by reference herein is the following:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Exhibit 1<FONT STYLE="font-family: Symbol">:</FONT>&nbsp;Registrant's
press release entitled: &ldquo;RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on March 26&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This Form 6-K is incorporated by reference into the Company's Registration
Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October
29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122)
and on July 24, 2019 (File No. 333-232776) and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission
on February 25, 2016 (Registration No. 333-209702), on July 23, 2018 (File No. 333-226278) and on July 24, 2019 (File No. 333-232777).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SIGNATURES</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 28.35pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Pursuant to the requirements of&nbsp;the&nbsp;Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 220.65pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="text-align: left; ">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; "><FONT STYLE="font-size: 10pt">REDHILL BIOPHARMA LTD.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; ">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; "><FONT STYLE="font-size: 10pt">(the &quot;Registrant&quot;)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; ">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 51%; text-align: left; ">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left; ">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: left; ">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 16%; text-align: left; ">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt">Date: March 23, 2020</FONT></TD>
    <TD STYLE="text-align: left; "><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left; "><FONT STYLE="font-size: 10pt">/s/
Dror Ben-Asher</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left;">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left; ">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; "><FONT STYLE="font-size: 10pt">Dror Ben-Asher&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; ">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left; ">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; "><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; ">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>exh_1.htm
<DESCRIPTION>EXHIBIT 1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><b>Exhibit 1</b></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><FONT STYLE="background-color: white"><B><U>RedHill Biopharma to
Present at Virtual Life Sciences Investor Forum on March 26<BR>
</U></B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>TEL-AVIV, Israel and RALEIGH, N.C., March 23, 2020 </B>RedHill
Biopharma Ltd. (Nasdaq: RDHL) (&ldquo;RedHill&rdquo; or the &ldquo;Company&rdquo;), a specialty biopharmaceutical company focused
on gastrointestinal diseases, today announced that Guy Goldberg, RedHill's Chief Business Officer, will present a corporate overview
at the Virtual Life Sciences Investor Forum on Thursday, March 26, 2020, at 9:30 a.m. EDT.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This will be a live, online presentation where the audience is invited
to ask the Company questions in real-time. <FONT STYLE="background-color: white">The live broadcast and Q&amp;A session can be
accessed via the Company's website,&nbsp;</FONT>http://ir.redhillbio.com/events. <FONT STYLE="background-color: white">Please access
the website at least 15 minutes ahead of the presentation to register.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A replay of the presentation will be available for 30 days via the
Company&rsquo;s website: http://ir.redhillbio.com/events.&#9;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>About RedHill Biopharma&#9;<BR>
</B>RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company focused on gastrointestinal diseases. RedHill
promotes the gastrointestinal drugs, <B>Talicia<SUP>&reg;</SUP></B> for the treatment of <I>Helicobacter pylori (H. pylori)</I>
infection in adults<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT> and <B>Aemcolo<SUP>&reg;</SUP></B> for the treatment of
travelers&rsquo; diarrhea in adults<FONT STYLE="font-size: 10pt"><SUP>2</SUP></FONT>. RedHill acquired rights to <B>Movantik<SUP>&reg;
</SUP></B>for opioid-induced constipation in adults<FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT>. The acquisition remains
subject to certain customary closing conditions and regulatory clearances. RedHill&rsquo;s key clinical late-stage development
programs include: (i) <B>RHB-104</B>, with positive results from a first Phase 3 study for Crohn's disease; (ii) <B>RHB-204</B>,
with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (iii) <B>RHB-102</B> (<B>Bekinda<SUP>&reg;</SUP></B>),
with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for
IBS-D; (iv) <B>Opaganib (Yeliva<SUP>&reg;</SUP>)</B>, a first<B>-</B>in<B>-</B>class SK2 selective inhibitor, targeting multiple
oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 1/2a study for cholangiocarcinoma; (v) <B>RHB</B>-<B>106</B>,
an encapsulated bowel preparation, and (vi) <B>RHB-107</B>, a Phase 2-stage first-in-class, serine protease inhibitor, targeting
cancer and inflammatory gastrointestinal diseases. More information about the Company is available at www.redhillbio.com.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">_______________________</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT> Full prescribing
information for Talicia<SUP>&reg;</SUP> (omeprazole magnesium, amoxicillin, and rifabutin) is available at: www.Talicia.com</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP></FONT> Full prescribing information for
Aemcolo<SUP>&reg;</SUP> (rifamycin) is available at: www.Aemcolo.com.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT> Full prescribing information for
Movantik&reg; (naloxegol) is available at: www.Movantik.com. </P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>About Life Sciences Investor Forum</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Life Sciences Investor Forum is the leading proprietary investor
conference series that provides an interactive forum for Life Sciences companies to meet and present directly with investors.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A real-time solution for investor engagement, Life Sciences Investor
Forum is part of Intrado&rsquo;s suite of investor relations services specifically designed for more efficient Investor Access.
Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing
and investor communications capabilities with a comprehensive global investor audience network. Learn more about the event at www.lifesciencesinvestorforum.com.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>About Intrado</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Intrado, Formerly West, is an innovative, cloud-based, global technology
partner to clients around the world. Our solutions connect people and organizations at the right time and in the right ways, making
those mission-critical connections more relevant, engaging, and actionable-turning Information to Insight.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>This press release contains &ldquo;forward-looking statements&rdquo;
within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words &ldquo;intends,&rdquo;
&ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;plans,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;projects,&rdquo;
&ldquo;predicts,&rdquo; &ldquo;estimates,&rdquo; &ldquo;aims,&rdquo; &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;potential&rdquo;
or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks
and uncertainties, many of which are beyond the Company&rsquo;s control and cannot be predicted or quantified, and consequently,
actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties
include, without limitation, risks related to the timing of hiring sales representatives as well as risks and uncertainties associated
with (i) the initiation, timing, progress and results of the Company&rsquo;s research, manufacturing, preclinical studies, clinical
trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its therapeutic candidates
and its FDA-approved products; (ii) the Company&rsquo;s ability to advance its therapeutic candidates into clinical trials or to
successfully complete its preclinical studies or clinical trials or the development of a commercial companion diagnostic for the
detection of MAP; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company&rsquo;s
receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback;
(iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company&rsquo;s therapeutic candidates
and Talicia<SUP>&reg;</SUP>; (v) the Company&rsquo;s ability to successfully commercialize and promote Talicia<SUP>&reg;</SUP>
and Aemcolo<SUP>&reg; </SUP><FONT STYLE="background-color: white">and following closing of the acquisition, Movantik<SUP>&reg;</SUP></FONT>;
(vi) the Company&rsquo;s ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products
approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities;
(viii) the interpretation of the properties and characteristics of the Company&rsquo;s therapeutic candidates and the results obtained
with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company&rsquo;s
business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to
establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business
without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property
defaulting in their obligations to the Company; (xii) estimates of the Company&rsquo;s expenses, future revenues, capital requirements
and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under
the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company&rsquo;s industry;
and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the
risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on March 4, 2020. All forward-looking
statements included in this press release are made only as of the date of this press release. The Company assumes no obligation
to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless
required by law.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 54%">
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>Company contact:</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">Adi Frish</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">Senior VP Business Development &amp; Licensing</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">RedHill Biopharma</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">+972-54-6543-112</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">adi@redhillbio.com</P></TD>
    <TD STYLE="width: 46%">
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>IR contact (U.S.):</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">Timothy McCarthy, CFA, MBA</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">Managing Director, Relationship Manager</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">LifeSci Advisors, LLC</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">+1-212-915-2564</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">tim@lifesciadvisors.com</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
